Amai Proteins is a technology company.
Amai Proteins has raised $1.0M across 1 funding round.
Amai Proteins has raised $1.0M in total across 1 funding round.
Amai Proteins has raised $1.0M in total across 1 funding round.
Amai Proteins's investors include Inovexus.
Amai Proteins is a food tech company developing designer sweet proteins as a healthy, sustainable sugar alternative through computational protein design and precision fermentation. Its flagship product, Sweelin™, is a calorie-free protein 3,000 times sweeter than sugar, enabling food manufacturers to reduce sugar by 40-70% while delivering a sugar-like taste, high stability, and no impact on blood glucose or insulin levels.[1][2][4][5][7] The company serves food and beverage producers worldwide, addressing sugar's role as a leading health threat by offering a cost-effective, eco-friendly solution that prevents billions of kilograms of sugar consumption annually, saves water and land, and cuts healthcare costs.[3][5][6] With regulatory approvals like US self-affirmed GRAS and FEMA GRAS, and plans for FDA approval, Amai is scaling production in facilities including Bangalore, targeting high-diabetes markets and sugar-tax regions amid rising demand for natural, functional ingredients.[4][7]
Founded in 2016 by Dr. Ilan Samish, a protein scientist, biochemistry lecturer, and entrepreneur, Amai Proteins emerged from Samish's mission to combat sugar as "public enemy number one" by redesigning naturally occurring sweet proteins from tropical plants for mass-market use.[2][5] Inspired by research on rare sweet proteins discovered in jungles of Malaysia, China, and West Africa, Samish applied his expertise in Agile Integrative Computational Protein Design (AI-CPD) to create hyper-sweet, stable variants producible via yeast fermentation, akin to brewing beer.[1][2][3] Early milestones included raising $17M in Series A funding, winning the Extreme Tech Challenge in 2022 (after being a 2020 finalist), and transitioning from proof-of-concept R&D to scalable pilot facilities for faster testing with food partners.[2][5] The company has since expanded its Pro³ Platform beyond sweets to non-sweet proteins for meat, milk, and plants, humanizing its goal to "cure" the food system one protein at a time.[1][5]
Amai stands out in the alt-sweetener space through its protein-first approach, leveraging biotech for superior performance:
Amai rides the global war on sugar, fueled by WHO warnings on non-communicable diseases, rising diabetes (especially in taxed or high-prevalence markets), and consumer demand for clean-label, natural alternatives amid climate pressures on agriculture.[2][4][5][7] Timing is ideal post-2020s fermentation breakthroughs and David Baker's Nobel-winning computational protein design, which Amai directly builds on for scalable biomanufacturing.[7] Market forces like sugar taxes, health regulations, and sustainability mandates favor its low-cost, high-impact model, disrupting a fragmented $100B+ sweetener industry while enabling quick sugar cuts (40-70%) via partnerships with F&B giants.[3][5] By open-sourcing protein design for food system repair, Amai influences precision fermentation's rise, feeding 10B people sustainably without resource strain.[1][5][6]
Amai is poised for explosive growth with FDA approval expected in 2025, global expansion (Brazil, UAE), and Sweelin™ commercialization, potentially removing massive sugar volumes via multinational collaborations.[4][7] Its Pro³ Platform will drive diversification into alt-meat/milk proteins, capitalizing on AI-biotech convergence and fermentation's maturation. As sugar scrutiny intensifies and climate tech scales, Amai's influence could redefine mass-market proteins, delivering health and planetary wins—like its namesake "sweet" promise from jungle origins to everyday foods.[1][2][6]
Amai Proteins has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $1.0M Seed | Inovexus |